Please login to the form below

Not currently logged in
Email:
Password:

FDA approval

This page shows the latest FDA approval news and features for those working in and with pharma, biotech and healthcare.

NICE leaves the ‘the NHS door’ open despite rejecting Bayer’s Vitrakvi

NICE leaves the ‘the NHS door’ open despite rejecting Bayer’s Vitrakvi

Vitrakvi was the first out of the two to gain approval in the EU, for the treatment of adult and paediatric patients with solid tumours that display a NTRK gene fusion, ... Rozyltrek won FDA approval in August, and is currently being reviewed for

Latest news

More from news
Approximately 29 fully matching, plus 983 partially matching documents found.

Latest Intelligence

  • As the opioid crisis grabs the headlines, the search for safe treatments continues As the opioid crisis grabs the headlines, the search for safe treatments continues

    for opioid addiction, and the long-acting injectable Perseris for schizophrenia in adults, which got FDA approval this year.

  • The Cystic Fibrosis Buyers’ Club The Cystic Fibrosis Buyers’ Club

    The movement proved to be hugely influential, and by the early 1990s its activism had spurred the FDA to introduce ‘accelerated approval’ that allowed experimental yet promising drugs to be made ... The FDA hadn’t been willing to override its

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    Frontline monotherapy in NSCLC. The next regulatory milestone for Keytruda will be FDA approval as a first-line monotherapy in locally advanced or metastatic non-squamous or squamous non-small cell ... The FDA had been expected to grant approval in

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Vitrakvi(larotrectinib) gained FDA approval in late November to treat any solid tumours that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, which causes the production of TRK, a family ... The product gained EMA approval in November and

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    from clinical trials to FDA approval in just over two years. ... On one hand, it has scored a major success this year by gaining US and EU approval as a monotherapy maintenance treatment for NSCLC patients with inoperable stage 3 disease, ie

More from intelligence
Approximately 0 fully matching, plus 31 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics